Literature DB >> 9752025

[Management of psoriasis in family practice is now in closer agreement with the guidelines of the Netherlands Society of Family Physicians].

G A Donker1, M Foets, P Spreeuwenberg, G T van der Werf.   

Abstract

OBJECTIVE: To assess changes in incidence of psoriasis and to study changes in the management of psoriasis in general practice after the sending of guidelines on management of psoriasis to general practitioners (GPs) by the NHG.
DESIGN: Secondary data analysis.
SETTING: Netherlands Institute for Health Care Research (NIVEL), Utrecht, the Netherlands.
METHOD: Data on the incidence of psoriasis and its management by general practitioners were collected from a file predating the publication of the NHG guideline 'Psoriasis' in 1994, namely the 'Dutch National Survey of General Practice' (NS; 1987/'88), and from a subsequent file, the 'Registration Network Groningen' (RNG; 1995).
RESULTS: In the NS there were 106 new patients with psoriasis (incidence: 1.3/1000/year; 95% confidence interval (95% CI): 1.2-1.4) while in the RNG there were 24 (incidence: 1.2/1000/year; 95% CI: 0.7-1.9). In all, there were 466 psoriasis patients in the NS and 125 in the RNG. The number of referrals to dermatologists was halved in 1995 (7.2%) compared with 1987/'88 (14.4%; p < 0.05). The most frequently prescribed dermatologica in psoriasis was in 1995 corticosteroid group 3 (32.8%; in 1987/'88: 28.5%), but the rise was stronger in corticosteroid group 2 (29.6%; in 1987/'88: 16.0%; p < 0.001) and group 4 (16.0%; in 1987/'88: 8.8%; p < 0.05).
CONCLUSION: The incidence of psoriasis in general practice had not changed between 1987/'88 en 1995. Referral pattern and prescription shifted towards the guidelines issued by the NHG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9752025

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.

Authors:  Ashok Jha; Alex Upton; William C N Dunlop; Ron Akehurst
Journal:  Adv Ther       Date:  2015-09-05       Impact factor: 3.845

2.  Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.

Authors:  Jui-Ming Liu; Cheng-Ping Yu; Heng-Chang Chuang; Chun-Te Wu; Ren-Jun Hsu
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-01-28       Impact factor: 5.554

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.